The unified cardiometabolic disease continuum: mechanistic stages of a single pathophysiological process - Takeaways - MDSpire

The unified cardiometabolic disease continuum: mechanistic stages of a single pathophysiological process

  • By

  • Luz María Quirino-Vela

  • Miguel A. Mayoral-Chávez

  • Carlos A. Matías-Cervantes

  • Yobana Pérez-Cervera

  • Iván A. García-Montalvo

  • Juan Alpuche

  • July 9, 2026

  • 0 min

Share

  • 1

    Type 2 diabetes mellitus, atherosclerotic cardiovascular disease, and other conditions represent endpoints of a unified cardiometabolic continuum.

  • 2

    Visceral adipose tissue dysfunction and ceramide-mediated lipotoxicity are key mechanisms in the progression of cardiometabolic disorders.

  • 3

    Stage-specific biomarkers such as ceramides and TMAO are identified as important mediators in the unified cardiometabolic disease continuum.

  • 4

    GLP-1 receptor agonists and SGLT2 inhibitors demonstrate benefits across multiple cardiometabolic conditions, reflecting shared biological processes.

  • 5

    The review advocates for a mechanistic UCD model to inform risk stratification, biomarker development, and targeted therapies.

Original Source(s)

Related Content